The study of how long NEJM's anti-neo-corona immunity lasts to more than 10,000 people provides new clues

However, whether patients infected with the new coronavirus will re-infect can also provide clues to the durability of the immune response.
we have heard sporadic reports of re-infection since the outbreak, but there is still little systematic research on re-infection.
A recent study published in the New England Journal of Medicine (NEJM) followed up with more than 12,000 health care workers working in the UK and found that patients with antibodies to the new coronavirus spike protein and nucleocapsids significantly reduced their risk of contracting the new coronavirus again within the next six months.
good news for people worried about the durability of vaccine protection.
study, a forward-looking follow-up trial was conducted among health care workers working in four hospitals at Oxford University Hospital.
Starting april 23 this year, these health care providers were tested for nasopharyngeal swab nucleic acid every two weeks and serological tests every two months, according to data from the NEJM study as of November 30.
test results showed that a total of 12,541 people were tested for baseline anti-prickly protein antibodies, of which 11364 (90.6%) were serotype negative, 1177 (9.4%) were serotype positive, and 88 were serotype transformation during the study.
in subsequent follow-up, 223 of the 11,364 health care workers with a negative serotype tested positive for nucleic acid, of whom 100 showed symptoms and 123 showed no symptoms.
of the 1,265 health care workers who tested positive for serotypes, only two tested positive for nucleic acid and showed no symptoms.
based on these data, the researchers calculated that health care workers with a negative anti-prickly protein serotonin had a nucleic acid-positive risk index of 1.09 (1.09 per 10000 days at risk) and a serotonin-positive group of 0.13.
because the prevalence of the new crown outbreak in the UK has also changed over the study period, the number of nucleic acid positives detected each month from April to November is different.
the proportion of nucleic acid positives in health care workers who did not test positive for serotypes was significantly lower than in the serotype-negative group.
The new coronavirus nucleic acid test positive data observed from April to November this year (red line is serotype negative group, blue line is serotype positive group, photo source: Reference: Reference 1)) Researchers also used anti-neocoviral nucleoprotein antibodies as biomarkers to classify health care workers, the results are very similar to the results obtained using anti-pyrethroid protein classification.
Further analysis showed that the occurrence of nucleic acid positives was inversely related to the titration of anti-prickly protein antibodies and anti-nuclear shell protein antibodies (p.lt;0.001), even though the antibody titration level was below the serotype-positive standard, and this anti-correlation relationship persisted.
relationship curve between the positive rate of nucleic acid testing and antibody titration (left, anti-prick protein antibody; right, anti-nuclear crust protein antibody, vertical dotted line marks serotype positive standard).
Photo Source: Supplied) In this study, the presence of anti-prickly protein antibodies significantly reduced the risk of new coronary nucleic acid testing positive for the next 31 weeks.
means that the immune response from previous coronavirus infections can provide protection for most people for at least six months.
researchers also point to some of the shortcomings of the study, as the number of cases among sero-positive health care workers is so low that they can't tell what causes the patients to re-infect.
the study also lacked sequencing data to show how different the re-infected virus genome sequence was from the first infected virus sequence.
31-week follow-up period is still relatively short.
The follow-up is still ongoing, and the researchers will use more biomarkers to monitor the body fluids and cellular immune response to the new coronavirus, to learn more about the strength and duration of the immune response, and their relationship to protection against re-infection and severe COVID-19.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
resources: s1. Lumley et al. (2020) Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. The New England Journal of Medicines, DOI: 10.1056/NEJMoa2034545。